RG
HZNP

Redmile Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Redmile Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-913,319
Closed -$72.8M – 78
2022
Q2 		$72.8M Buy
+913,319
New +$86.5M 2.78% 7
2019
Q4 		– Sell
-14,700
Closed -$400K – 87
2019
Q3 		$400K Buy
14,700
+3,300
+29% +$85.3K 0.01% 60
2019
Q2 		$274K Buy
+11,400
New +$289K 0.01% 73
2018
Q3 		– Sell
-25,800
Closed -$427K – 101
2018
Q2 		$427K Buy
25,800
+5,800
+29% +$88.4K 0.01% 69
2018
Q1 		$284K Hold
20,000
– – 0.01% 61
2017
Q4 		$292K Buy
+20,000
New +$281K 0.01% 63

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return